The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism
European Endocrinology · 2014 · 10 (2) · 151
DOI: 10.17925/ee.2014.10.02.151 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Endocrinology, 2014. Verfasst von Tamer Shalaby und 3 weiteren Autor:innen. Beteiligte Einrichtung: Registrar in Acute Medicine and Endocrinology. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Denosumab is a monoclonal antibody which is currently licensed in the UK drug market for the prevention of skeletal-related events secondary to malignancy (excluding myeloma). This monoclonal antibody is a 6 monthly subcutaneous injection that works by lowering calcium levels. When used in a 90 year old patient with primary hyperparathyroidism it demonstrated a dramatic reduction in the calcium level which had proven difficult to reduce by bisphosphonates and who was not a candidate for surgical intervention.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Registrar in Acute Medicine and Endocrinology.
- CT1 Endocrinology.
- Consultant Endocrinologist, Maidstone Hospital, Maidstone, Kent, UK.
Zitieren
APA
Shalaby, T., Anandappa, S., Sivappriyan, S., & Kumar, J. (2014). The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism. European Endocrinology, 10(2), 151. https://doi.org/10.17925/ee.2014.10.02.151
Vancouver
Shalaby T, Anandappa S, Sivappriyan S, Kumar J. The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism. European Endocrinology. 2014;10(2):151. doi:10.17925/ee.2014.10.02.151
BibTeX
@article{Shalaby2014,
author = {Shalaby, Tamer and Anandappa, Samantha and Sivappriyan, Siva and Kumar, Jesse},
title = {The Use of Denosumab in a Nonagenarian with Primary Hyperparathyroidism},
journal = {European Endocrinology},
year = {2014},
volume = {10},
number = {2},
pages = {151},
doi = {10.17925/ee.2014.10.02.151}
}
EUVIMED